Azapropazone


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Acute gout 1.8 g/day in divided doses, then 1.2 g/day in divided doses. Ankylosing spondylitis; Rheumatoid arthritis 1.2 g/day in 2-4 divided doses.
Dosage Details
Oral
Acute gout
Adult: 1.8 g daily in divided doses until acute symptoms subside, then reduce to 1.2 g daily in divided doses until symptoms disappear.
Elderly: 1.8 g daily in divided doses for 1st 24 hr, then 1.2 g daily in divided doses. Reduce further to max 600 mg daily as soon as possible. Continue only until acute symptoms resolve.

Oral
Ankylosing spondylitis, Rheumatoid arthritis
Adult: 1.2 g daily in 2-4 divided doses.
Elderly: >60 yr: 300 mg bid.
Renal Impairment
CrClDosage
<50Reduce dose by one-half to two-thirds.
50-75Reduce dose by one-third to one-half.
Administration
Should be taken with food. Take w/ or immediately after meals.
Contraindications
History of peptic ulceration, porphyria, inflammatory bowel disease, blood disorders, hypersensitivity. Not to be used in acute gout of elderly with even mild renal function. Lactation. Severe renal disease.
Special Precautions
Allergic disorders, coagulation defects; renal, cardiac or hepatic impairment; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, pregnancy. Should be withdrawn if GI lesions develop. Long-term use of NSAID is associated with reversible, reduced female fertility. Maintain adequate fluid intake.
Adverse Reactions
GI disorders; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity, haematuria; blood disorders, fluid retention, hypertension.
Drug Interactions
Enhances effects of oral anticoagulants (warfarin), phenytoin and sulfonylureas. Increased plasma concentration of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity when used with ACE inhibitors, cyclosporin, tacrolimus or diuretics; hypokalaemia may also result from ACE inhibitors and diuretics concomitant use. Quinolones may produce convulsions. Moclobemide enhances NSAIDs effects. Increased risk of adverse reactions with other NSAIDs. Increased risk of GI bleeding and ulceration with corticosteroids, SSRIs, clopidrogel and ticlopidine, biphosphonates or pentoxifylline; haemotoxicity with zidovudine. Ritonavir increases plasma concentration; mifepristone and antihypertensives alter the drug's efficacy.
Action
Description: Azapropazone is an NSAID structurally related to phenylbutazone which also has uricosuric properties.
Disclaimer: This information is independently developed by MIMS based on Azapropazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in